agilon health, inc. (NYSE: AGL) stock experienced a significant drop of 5.07% in the pre-market trading session on Friday, following the release of its full-year results and analysts' revised forecasts.
The healthcare company reported revenue in line with expectations at $6.1 billion for the fiscal year. However, it reported a larger-than-expected statutory loss of $0.63 per share, which raised concerns among investors.
Analyst projections for the upcoming year have been revised, with revenue estimates lowered to $6.10 billion, approximately in line with the previous year. Additionally, analysts expect agilon health's revenue growth to slow substantially, projecting an annualized growth rate of 0.6% compared to the historical five-year growth rate of 38%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。